TOTAL: $575.025M |
||||
Company (Symbol)# | Type Of Financing | Number Of Shares, Units Or Warrants (M) | Amount Raised (M) | Investors; Placement Agents; Details (Date)@ |
Abgenix Inc. (ABGX) | Private placement of common stock | 3.3S | $230 | Abgenix entered into definitive purchase agreements for the sale of about 3.3M shares to selected institutional and other accredited investors for about $230M, or $70 per share; Robertson Stephens served as the placement agent (11/1) |
Aradigm Corp. (ARDM) | Equity financing agreement | N/A | -- | Aradigm entered into a definitive agreement with Acqua Wellington North American Equities Fund Ltd. for the sale of up to $50M in stock over the next 20 months (11/8) |
Aronex Pharmaceuticals Inc. (ARNX) | Equity | N/A | -- | Aronex entered a definitive agreement with Acqua Wellington North American Equities Fund Ltd. for equity financing covering the sale of up to $24M of Aronex's common stock during the next 28 months (11/30) |
Aviron (AVIR) | Private placement of common stock | .15S | $8 | Aviron sold 153,448 shares to Acqua Wellington North American Equities Fund Ltd. for $8M, or $52.13 per share; the purchase price was determined based on the volume weighted average market price for an 18-day trading period (11/1) |
Aviron (AVIR) | Private placement of common stock | .143S | $8 | Aviron sold 143,512 shares to Acqua Wellington North American Equities Fund Ltd. at $55.74 per share for $8M (11/29) |
BresaGen Ltd. (Australia; AMEX:BGN) | Private placement of common stock | 10S | $15.3 | BresaGen raised $15.3M through the issuance of 10M shares (11/17) |
Calypte Biomedical Corp. (CALY) | Equity line financing | N/A | -- | Calypte secured an equity line facility through Ladenburg Thalmann & Co. Inc. for $25M through the issuance of common stock to a private investment fund in a series of drawdowns over a 12-month period (11/3) |
Cell Genesys Inc. (CEGE) | Private placement of common stock | .75S | $56.25 | Cell Genesys sold about .75M shares of Abgenix Inc. as part of an Abgenix private placement; the shares were sold at $70 each; Robertson Stephens Inc. acted as a placement agent (11/1) |
Cell Pathways Inc. (CLPA) | Private placement of common stock and warrants | 3.2S 3.2W | $7.375 | Cell Pathways sold 3.2M shares and 3.2M warrants for $7.375 for each combined share and warrant; the warrants are for the purchase of 1.35M shares at $12 per share; Janney Montgomery Scott LLC and Jackson Boulevard Ventures LP acted as placement agents (11/10) |
Connetics Corp. (CNCT) | Public offering of InterMune Pharmaceuticals' shares | .9S | $42.2 | Connetics raised $42.2M through the sale of 900,000 InterMune Pharmaceuticals' shares, reducing its stake in the company (11/16) |
Curis Inc. (CRIS) | Private placement of common shares | 5.2S | $46.8 | Curis raised $46.8M through the placement of 5.2M shares; Prudential Vector Healthcare Group acted as the placement agent (11/16) |
DepoMed Inc. (AMEX:DMI) | Private placement of units | 50U | $5 | DepoMed agreed to sell 50 units, consisting of 28,571 shares of common stock and four-year warrants to purchase about 7,143 shares of common stock at $5.50 per share, to OrbiMed Advisors LLC (11/3) |
Endovasc Ltd. Inc. (OTC BB: ENDV) | Convertible preferred stock placement | N/A | $1.5 | Endovasc received the second $1.5M installment of a three-part $4.5M stock placement (11/14) |
Genta Inc. (GNTA) | Private placement of common stock | 4.29S | $28.9 | Genta Inc. raised $28.9M in cash from the sale of 4.29M shares; lead institutional investors included SAC Capital, Narragansett Capital and Proquest investments (11/13) |
Hemosol Inc. (Canada; TSE:HML) | Senior credit facility | N/A | -- | Hemosol signed a C$35M (US$22.7M) senior credit facility with the National Bank of Canada and the Bank of Nova Scotia (11/13) |
Matritech Inc. (NMPS) | Private placement of common shares | .23S | $1.2 | Matritech sold 230,713 shares of common stock to Acqua Wellington North American Equities Fund Ltd. for $1.2M, or $5.20 per share (11/17) |
NaPro BioTherapeutics Inc. (NPRO) | Private placement of common shares | 2S | $17.5 | NaPro raised $17.5M in the private placement; Stonegate Securities Inc. acted as placement agent (11/20) |
Phytopharm plc (UK; LSE:PYM.L) | Private placement of common shares | 1.76S | US$15.35 | Phytopharm raised US$15.35M through the private placement of 1.76M shares at 625 pence each (11/29) |
Rigel Pharmaceuticals Inc. (RIGL) | Private placement of common shares | 1.43S | $10 | Novartis AG purchased 1.43M shares of Rigel stock in a private placement held concurrently with Rigel's IPO (11/28) |
Steroidogenesis Inhibitors International Inc. (OTC BB:STGI) | Common stock purchase agreement | N/A | -- | STGI entered into an agreement with Fusion Capital Fund II LLC, whereby Fusion Capital will buy $10M of stock over a 25-month period; STGI also has the option to require Fusion Capital to enter into a second identical common stock purchase agreement for an additional $10M in common stock (11/13) |
Titan Pharmaceuticals Inc. (AMEX:TTP) | Private placement of common stock | 1.2S | $43.8 | Titan sold 1.2M shares for $36.50 each, raising $43.8M; the shares were sold to selected institutional investors (11/16) |
Valentis Inc. (VLTS) | Private offering of 5% convertible redeemable preferred stock | ND | $29 | Valentis raised $29M through the offering led by Perseus-Soros Biopharmaceutical Fund LP; Delta Opportunity Fund also participated (11/20) |
VidaMed Inc. (VIDA) | Private placement of common shares | 4.425S | $8.85 | VidaMed raised $8.85M through a private offering of 4.425M shares at $2 each (11/21) |
Notes: |
||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. |
||||
* Non-U.S. currencies converted at the exchange rate on the date of the announcement. |
||||
@ Dates refer to the date of the press release. |
||||
ASX = Australian Stock Exchange |
||||
|
LSE = London Stock Exchange |
||||
TSE = Toronto Stock Exchange |
||||
VSE = Vancouver Stock Exchange |
||||
OTC BB = Over The Counter Bulletin Board |
||||